Developing clinical indicators for oncology: the inaugural cancer care indicator set for the Australian Council on Healthcare Standards

- Segelov, Eva, Carrington, Christine, Emery, Jon D., Zhang, Phoebe, Cooper, Simon, O’Kane, Carmel, Wale, Janet, Hancock, Stephen J., Sulkowski, Anthony, Bashford, John, Aranda, Sanchia, Currow, David, Zalcberg, John R., Heriot, Alexander G., Mileshkin, Linda, Coutsouvelis, John, Millar, Jeremy L., Collopy, Brian T.

PARAGON: a phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors

- Tang, Monica, O'Connell, Rachel L., Amant, Frederic, Beale, Philip, McNally, Orla, Sjoquist, Katrin M., Grant, Peter, Davis, Alison, Sykes, Peter, Mileshkin, Linda, Moujaber, Tania, Kennedy, Catherine J., deFazio, Anna, Tan, King, Antill, Yoland, Goh, Jeffrey, Bonaventura, Tony, Scurry, James, Friedlander, Michael

Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: the PARAGON trial – ANZGOG 0903

- Mileshkin, Linda, Edmondson, Richard, O'Connell, Rachel L., Sjoquist, Katrin M., Andrews, John, Jyothirmayi, Rema, Beale, Philip, Bonaventura, Tony, Goh, Jeffrey, Hall, Marcia, Clamp, Andrew, Green, John, Lord, Rosemary, Amant, Frédéric, Alexander, Laura, Carty, Karen, Paul, James, Scurry, James, Millan, David, Nottley, Steven, Friedlander, Michael

Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial

- Blinman, Prunella, Mileshkin, Linda, O'Connell, Rachel, Creutzberg, Carien L., Stockler, Martin R., Khaw, Pearly, Goss, Geraldine, Johnson, Carol, Capp, Anne, Brooks, Susan, Wain, Gerard, Kolodziej, Ilka, Veillard, Anne-Sophie